Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Clinical Oncology

• Publication date

  1997-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1997.15.3.928PMID 9060530
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique.

  1996cited by this paper
• The Need for Standardized Pathologic Staging of Pancreaticoduodenectomy Specimens

  1996cited by this paper
• Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies

  1996cited by this paper
• Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head*

  1996cited by this paper
• Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group.

  1996cited by this paper
• Reoperative pancreaticoduodenectomy for periampullary carcinoma.

  1996cited by this paper
• Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?

  1995cited by this paper
• Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.

  1995cited by this paper
• Fine needle aspiration of the pancreas. In quest of accuracy.

  1995cited by this paper
• Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head.

  1995cited by this paper
• Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients

  1995cited by this paper
• Carcinoma of the periampullary region: who benefits from portal vein resection?

  1995cited by this paper
• Pancreatic malignancy involving the superior mesenteric-portal vein confluence is not a contraindication to pancreaticoduodenectomy

  1995cited by this paper
• The Effects of Regionalization on Cost and Outcome for One General High‐Risk Surgical Procedure

  1995cited by this paper
• Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms.

  1995cited by this paper
• Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.

  1994cited by this paper
• Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy.

  1993cited by this paper
• Recurrence of exocrine pancreatic cancer--local or hepatic?

  1993cited by this paper
• Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

  1993cited by this paper
• Intraoperative Radiation Therapy Following Pancreaticoduodenectomy

  1993cited by this paper
• Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography.

  1993cited by this paper
• A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.

  1993cited by this paper
• Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.

  1993cited by this paper
• Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.

  1993cited by this paper
• Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.

  1993cited by this paper
• Relation of Perioperative Deaths to Hospital Volume Among Patients Undergoing Pancreatic Resection for Malignancy

  1993cited by this paper
• Laparoscopic feeding jejunostomy tube in oncology patients.

  1992cited by this paper
• Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

  1992cited by this paper
• Adjuvant therapy of resected adenocarcinoma of the pancreas.

  1991cited by this paper
• Survival After Pancreatoduodenectomy: 118 Consecutive Resections Without an Operative Mortality

  1990cited by this paper
• Patterns of failure after curative resection of pancreatic carcinoma

  1990cited by this paper
• Preoperative staging and assessment of resectability of pancreatic cancer.

  1990cited by this paper
• Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region

  1989cited by this paper
• Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

  1985cited by this paper
• Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy.

  1983cited by this paper
• Preoperative irradiation in carcinoma of the pancreas

  1980cited by this paper
• Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973—Analysis of surgical failure and implications for radiation therapy

  1976cited by this paper

• Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma.

  2026cites this paper
• Risk Factors for Early Recurrence of Resectable Pancreatic Cancer

  2025cites this paper
• Self-expandable metal vs. plastic stents for preoperative biliary drainage in patients receiving neoadjuvant chemotherapy.

  2025cites this paper
• Multimodal Therapy for Pancreatic Cancer: State of the Art.

  2025cites this paper
• Preoperative downstaging of pancreatic cancer is associated with improved survival after multi-agent chemotherapy, but not after radiation.

  2023cites this paper
• Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis

  2023cites this paper
• Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma

  2023cites this paper
• Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters

  2023cites this paper
• Dual Tumor Exosome Biomarker Co-recognitions Based Nanoliquid Biopsy for the Accurate Early Diagnosis of Pancreatic Cancer.

  2023cites this paper
• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

  2023cites this paper
• Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

  2023cites this paper
• Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”

  2022cites this paper
• Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma

  2022cites this paper
• Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy

  2022cites this paper
• One hundred most cited article related to pancreaticoduodenectomy surgery: A bibliometric analysis.

  2022cites this paper
• Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma

  2021influential citation
• Imaging Assessment of Pancreatic Cancer Resectability after Neoadjuvant Therapy: AJR Expert Panel Narrative Review.

  2021cites this paper
• Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer.

  2021cites this paper
• A review of response in neoadjuvant therapy for exocrine pancreatic cancer

  2021cites this paper
• Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma

  2021cites this paper
• Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer

  2021cites this paper
• The Landmark Series: Preoperative Therapy for Pancreatic Cancer

  2021cites this paper
• A systematic study of novel drug delivery mechanisms and treatment strategies for pancreatic cancer

  2021cites this paper
• Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis

  2021cites this paper
• Preoperative biliary drainage for pancreatic cancer

  2021cites this paper
• Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer

  2021cites this paper
• Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria

  2021cites this paper
• Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.

  2020cites this paper
• ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer.

  2020cites this paper
• Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection.

  2020cites this paper
• ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer

  2020cites this paper
• Advances and challenges of neoadjuvant therapy in pancreatic cancer

  2020cites this paper
• Distal pancreatectomy with celiac axis resection for locally advanced pancreatic carcinoma: case report

  2020cites this paper
• Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

  2020cites this paper
• Update on Management Periampullary/Pancreatic Head Cancer

  2020cites this paper
• A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer.

  2020cites this paper
• Optimal timing and treatment strategy for pancreatic cancer

  2020influential citation
• The role of radiation for pancreatic adenocarcinoma

  2020cites this paper
• Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?

  2019cites this paper
• Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review

  2019cites this paper
• Resectable and Borderline Resectable Pancreatic Cancer

  2019cites this paper
• Clinical impact of additional therapy for residual pancreatic cancer

  2019cites this paper
• Goals of Treatment Sequencing for Localized Pancreatic Cancer

  2019cites this paper
• Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.

  2019cites this paper
• Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review

  2019cites this paper
• Preoperative Endoscopic Retrograde Cholangiopancreatography Is Not Associated With Increased Pancreatic Cancer Mortality.

  2019cites this paper
• Improved Survival after Administration of Neoadjuvant Chemotherapy in Patients with Clinical Stage I/II Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• Pancreatic and Periampullary Cancer

  2019cites this paper
• Initial Experience in the Treatment of ‘ ‘ Borderline Resectable ’ ’ Pancreatic Adenocarcinoma §

  2019cites this paper
• Cutting‐edge strategies for borderline resectable pancreatic cancer

  2019cites this paper
• A CARE-compliant case report: total pancreatectomy and total gastrectomy to treat pancreatic ductal adenocarcinoma

  2019cites this paper
• Neoadjuvant Chemoradiation Therapy is Associated with Adverse Outcomes in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Cancer

  2019cites this paper
• Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer.

  2019cites this paper
• Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer

  2019cites this paper
• Pancreatic Cancer and Possible Therapeutic Options

  2019cites this paper
• Delivery of Neoadjuvant Versus Adjuvant Therapy in Localized Pancreatic Cancer

  2019cites this paper
• Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

  2018cites this paper
• Postoperative hepatic arterial infusion chemotherapy improved survival of pancreatic cancer after radical pancreatectomy: a retrospective study

  2018cites this paper
• Pathology Reporting of Resected Pancreatic/Periampullary Cancer Specimen

  2018cites this paper
• Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma

  2018cites this paper
• Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma

  2018cites this paper
• Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

  2018cites this paper
• Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX

  2018cites this paper
• Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer.

  2018cites this paper
• Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins

  2018cites this paper
• Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

  2018cites this paper
• Age as a prognostic indicator for adjuvant therapy in patients who underwent pancreatic resections for cancer.

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Safety and efficacy of self-expanding metal stents for biliary drainage in patients receiving neoadjuvant therapy for pancreatic cancer

  2018cites this paper
• Value of lymph node positivity in treatment planning for early stage pancreatic cancer

  2017cites this paper
• implemented. For patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), a number of clinical trials have been conducted; NACRT was demonstrated to improve resectability, R0 resection rate, overall survival rate, disease-free survival rate and even

  2017cites this paper
• The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.

  2017cites this paper
• Gastrointestinal cancer: Pancreas

  2017cites this paper
• BJRD17165 1..8

  2017cites this paper
• Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.

  2017cites this paper
• Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis

  2017influential citation
• Neoadjuvant chemoradiation for non‐metastatic pancreatic cancer increases margin‐negative and node‐negative rates at resection

  2017cites this paper
• Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer.

  2017cites this paper
• Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities.

  2017cites this paper
• Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma

  2017cites this paper
• Patterns and Determinants of Recurrence for Pancreatic Ductal Adenocarcinoma after Resection

  2017cites this paper
• Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.

  2017cites this paper
• Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

  2017cites this paper
• New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer.

  2017cites this paper
• Past, Present, and Future of Neoadjuvant Therapy for Pancreatic Cancer

  2017cites this paper
• A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes

  2017cites this paper
• Integration of different criteria for borderline resectable pancreatic cancer using classification tree analysis: the use of radiological tumour-vascular interface in correlation with surgical and pathological outcomes.

  2017cites this paper
• Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cites this paper
• Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma.

  2017cites this paper
• Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma.

  2017cites this paper
• Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.

  2016cites this paper
• Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma

  2016cites this paper
• Role of Systemic Therapy

  2016cites this paper
• Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications

  2016cites this paper
• The role of neoadjuvant therapy in pancreatic cancer: a review.

  2016cites this paper
• Top classic citations in pancreatic cancer research

  2016cites this paper
• Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy

  2016cites this paper
• Locally advanced pancreatic cancer — new therapeutic challenges

  2016cites this paper
• Neoadjuvant Therapy for Resectable Pancreatic Adenocarcinoma

  2016cites this paper
• Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.

  2016cites this paper